Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistent Cancers

Treatment Resistent Cancers

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Immune checkpoint therapy in pediatric and adolescent lymphomas.

Haematologica·2026

Same author

TRAM-01: A phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.

Neuro-oncology·2026

Same author

Adding induction intrathecal cytarabine in newly diagnosed CNS2 B-acute lymphoblastic leukemia does not improve outcomes.

Blood advances·2026

Same author

Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-cell acute lymphoblastic leukemia.

Blood advances·2026

Same author

Group 4 Medulloblastomas of Early Childhood Treated With High-Dose Chemotherapy- and Craniospinal Irradiation-Sparing Approach.

Pediatric blood & cancer·2026

Same author

Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Search research articles

Related Experiment Video

Updated: Mar 29, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Emerging immunotherapy in pediatric lymphoma.

Craig Erker¹, Paul Harker-Murray¹, Michael J Burke¹

¹Division of Pediatric Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

Future Oncology (London, England)

|December 1, 2015

Summary

Pediatric lymphoma treatments are advancing with immunotherapy, offering new hope for children with relapsed or refractory disease. This review explores current and emerging immunotherapies for childhood Hodgkin and non-Hodgkin lymphoma.

Keywords:

Hodgkin lymphoma checkpoint inhibitors immunotherapy non-Hodgkin lymphoma pediatric

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Related Experiment Videos

Last Updated: Mar 29, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Area of Science:

Pediatric Hematology Oncology
Cancer Immunology
Translational Cancer Research

Background:

Hodgkin and non-Hodgkin lymphoma are common pediatric cancers.
Relapsed or refractory disease in children has poor outcomes.
Immunotherapy is a rapidly evolving treatment modality for hematologic malignancies.

Purpose of the Study:

To provide an overview of current and emerging immunotherapies for pediatric lymphoma.
To highlight novel therapeutic approaches for childhood lymphomas.
To discuss the expanding armamentarium of immunotherapies in pediatric oncology.

Main Methods:

Literature review of current and emerging immunotherapies.
Analysis of novel agents including monoclonal antibodies, antibody-drug conjugates, and cellular therapies.
Focus on applications in pediatric Hodgkin and non-Hodgkin lymphoma.

Main Results:

Immunotherapy represents a novel approach with expanding options for pediatric lymphoma.
Agents like bispecific T-cell engagers and chimeric antigen receptor-engineered T cells show promise.
Many immunotherapies are in early stages but demonstrate efficacy in relapsed disease.

Conclusions:

Immunotherapy is a critical and expanding area in the treatment of pediatric lymphoma.
Emerging immunotherapies offer new hope for children with poor-prognosis lymphoma.
Continued research and development are essential for optimizing these novel treatments.